Maximize Beta-Blockers Before Starting Ivabradine
June 2015
Ivabradine (Corlanor, CORE-lah-nore) will be the first new drug approved for systolic heart failure in a decade.
It works by inhibiting the If or "funny" current in the sinoatrial node. This lowers heart rate...withOUT causing a drop in blood pressure.
Ivabradine prevents 1 in 25 patients from being hospitalized over 2 years...when ADDED to standard therapy including an ACEI or ARB, beta-blocker, and aldosterone antagonist. But it DOESN'T reduce overall mortality.
Get concise advice on drug therapy, plus unlimited access to CE
Hospital Pharmacist's Letter membership benefits include:
- 12 issues every year — what you need to know and do, right now
- Quick, practical reference charts and tools
- Comprehensive CE library to meet license renewal and state requirements
- Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
- Plus much more!
Choose the right tier for your needs today.
Already a subscriber? Log in
Volume pricing available. Get a quote